Medgend Icon


Janumet Xr FDA Approved Drugs

JANUMET [Metformin HydrochlorideC4H11N5ClH : Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
1gm : eq 50mg base (oral tablet)
500mg : eq 50mg base (oral tablet)
Merck Sharp DohmeMar 30, 2007
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUMET XR [Metformin HydrochlorideC4H11N5ClH : Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
1gm : eq 100mg base (oral tablet, extended release)
1gm : eq 50mg base (oral tablet, extended release)
500mg : eq 50mg base (oral tablet, extended release)
Merck Sharp DohmeFeb 2, 2012
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.